Android app on Google Play

Regeneron (REGN) Sees Upside Following Study on Lucentis/Avastin in DME

June 27, 2013 10:56 AM EDT Send to a Friend
Get Alerts REGN Hot Sheet
Price: $293.43 -3.18%

Rating Summary:
    15 Buy, 11 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 26 | Down: 10 | New: 8
Trade REGN Now!
Join SI Premium – FREE
Lucentis/Avastin DME data published in medical journal is positive for Regeneron's (NASDAQ: REGN) Eylea, thinks Goldman Sachs analyst Terence Flynn.

"In the published study, 48 DME patients were randomized to monthly Lucentis or Avastin at baseline and monthly re-treated based on central subfield thickness (CST, correlated with vision). After 48 weeks, a significant improvement in vision (13 letters for Lucentis and 11 for Avastin) and reduction in CST were seen with both drugs," said Flynn.

"The study supports our view that branded VEGF drugs (REGN's Eylea and Lucentis) are superior to off-label Avastin for DME, which is another potential Eylea growth driver," concluded the analyst.

Goldman Sachs maintained a Buy rating on Regeneron Pharma with a price target of $300.00.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $228.74 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Goldman Sachs

Add Your Comment